|
KMID : 0624620200530080400
|
|
BMB Reports
2020 Volume.53 No. 8 p.400 ~ p.412
|
|
|
Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment
|
|
Jayaramayya Kaavya
Mahalaxmi Iyer
Subramaniam Mohana Devi
Raj Neethu
Dayem Ahmed Abdal
Lim Kyung-Min
Kim Se-Jong
An Jong-Yub
Lee Yoon-Joo
Choi Yu-Jin
Kirubhakaran Arthi
Cho Ssang-Goo
Vellingiri Balachandar
|
|
|
Abstract
|
|
|
|
The world has witnessed unimaginable damage from the coronavirus disease-19 (COVID-19) pandemic. Because the pandemic is growing rapidly, it is important to consider diverse treatment options to effectively treat people worldwide. Since the immune system is at the hub of the infection, it is essential to regulate the dynamic balance in order to prevent the overexaggerated immune responses that subsequently result in multiorgan damage. The use of stem cells as treatment options has gained tremendous momentum in the past decade. The revolutionary measures in science have brought to the world mesenchymal stem cells (MSCs) and MSC-derived exosomes (MSC-Exo) as therapeutic opportunities for various diseases. The MSCs and MSCExos have immunomodulatory functions; they can be used as therapy to strike a balance in the immune cells of patients with COVID-19. In this review, we discuss the basics of the cytokine storm in COVID-19, MSCs, and MSC-derived exosomes and the potential and stem-cell-based ongoing clinical trials forCOVID-19.
|
|
|
KEYWORD
|
|
|
COVID-19, Exosome, Immunomodulation, Mesenchymal stem cells (MSCs), Ongoing Clinical trials, Therapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|